OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Antipsychotic drugs (APDs) are among the most widely prescribed medications. However, these drugs also cause profound metabolic disturbances including weight gain, glucose intolerance, and insulin resistance, and increase the risks of type 2 diabetes and cardiovascular disease. Significantly, all APDs cause metabolic side effects to differing degrees, and current treatments to reduce these metabolic symptoms have only limited efficacy. The single unifying property of all APDs is their blockade of dopamine D2-like receptors suggesting a role for these receptors in APD-induced metabolic dysfunction. Notably, we and others found that APDs not only act on dopamine receptors in the brain, but also act on the same receptors in the pancreas where they alter the release of hormones including insulin. These APD actions in the pancreas provide a critical new mechanism that may explain why antipsychotic drugs disrupt metabolic regulation and offer new treatment targets to improve these medications’ metabolic effects.
Zoom Details Below:
zoom.us/j/98643323773?pwd=bL0TW4vweAlQzIlL5VEFHKYiEaVYPl.1
Meeting ID: 986 4332 3773
Passcode: 758174
